Cerluten vs Vesugen

CNS-targeted peptide complex that modulates neuronal gene expression. Shown in Russian clinical studies to improve memory consolidation, attention, and protect against neurodegeneration.

Cerluten is a synthetic short peptide classified as a Khavinson-class bioregulator targeted at cerebral and central nervous system tissue, investigated for neuroprotective and anti-aging properties in neuronal cell populations through proposed gene expression regulatory mechanisms. Like other Khavinson bioregulator peptides, cerluten is proposed to reach target neuronal cells via amino acid transporter uptake — including proton-coupled oligopeptide transporters (POT) and large amino acid transporters (LAT) — and to modulate transcriptional activity in aging or damaged neural tissue. Published research on Khavinson-class ultrashort peptides has characterized intracellular transport via POT and LAT carriers and demonstrated gene expression regulatory effects across multiple tissue types, providing the class-level mechanistic framework within which cerluten's neuronal effects are proposed. Cerluten has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals. Cerluten dosing and respiratory applications Cerluten is classified as a bronchial tissue bioregulator in the Khavinson peptide research tradition, proposed to act on bronchial epithelial cells via amino acid transporter uptake and modulate gene expression related to respiratory tissue maintenance and oxidative stress response in aging airways. Preclinical and observational research in Eastern European clinical settings has examined cerluten in contexts of chronic bronchitis, age-related decline in respiratory function, and COPD support, with proposed mechanisms including anti-inflammatory gene regulation and bronchial epithelial cell cytoprotection. Standard Khavinson-class dosing protocols use oral capsule formulations in 10–20 day cycles at 5–10mg per cycle (divided doses), followed by rest intervals — consistent with the gene-regulatory rather than continuous-receptor-occupancy mechanism proposed for this peptide class. Independent peer-reviewed clinical trial evidence specific to cerluten is limited; efficacy data comes primarily from Khavinson Institute publications and observational reports. Cerluten is available from specialty Eastern European supplement and peptide vendors and is not approved by the FDA or EMA as a pharmaceutical. It is distinct from Chonluten, which targets lung parenchyma rather than bronchial epithelial tissue.

Tripeptide bioregulator targeting vascular endothelium; normalizes gene expression in smooth muscle and endothelial cells; reduces lipid accumulation in vessel walls

Vesugen is a synthetic peptide classified as a Khavinson-class bioregulator targeted at vascular endothelial and smooth muscle tissue, investigated for cytoprotective and anti-aging effects on the vascular wall through proposed gene expression regulatory mechanisms acting on endothelial and smooth muscle cell populations. Like other Khavinson bioregulator peptides, vesugen is proposed to modulate gene expression in target vascular cells through interactions with chromatin regulatory elements and transcription factor binding sites, with effects proposed to support endothelial integrity and vascular wall homeostasis under conditions of aging-related cellular stress. Published research on Khavinson-class short peptides has characterized systematic gene expression regulatory effects and cell differentiation regulatory capacity across multiple tissue types, providing the class-level mechanistic framework within which vesugen's vascular effects are proposed. Vesugen has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives entirely from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals.